RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Menno de Jong appointed director of RIVM Centre for Infectious Disease Control Starting 1 May 2024, Professor Menno de Jong will take on the role of director of RIVM’s Centre for Infectious Disease Control (CIb) . He succeeds Jaap van Dissel, who is retiring in April 2024.
Nitrogen and nature approach shows progress towards 2030, but targets are out of reach The nitrogen and nature measures that the government has implemented since 2021 are expected to make a positive contribution to the future quality of nature. The average exceedance of the critical loads for nitrogen deposition will decrease by a third up to 2030.
Natura 2000 sites: nitrogen deposition on the decline, but still too high for much of nature The amount of nitrogen deposited on nature reserves that are vulnerable to this is falling. However, this decline is not sufficient to meet the targets the Dutch government has set itself. This is the conclusion of the RIVM monitoring report ‘Nitrogen deposition in Natura 2000 areas 2023’.
Participation rates in cancer population screening programmes continue to decline The number of participants in the population screening programmes for breast cancer, cervical cancer and colorectal cancer continues to decline. This decline has been going on for years, reaching its lowest point in 2020.
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
From 1 October 2023, heel prick test also screens for metabolic disorder ALD From 1 October 2023, the blood of newborn babies will also be tested for the metabolic disorder adrenoleukodystrophy (ALD). This is done with the heel prick screening test.
NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
Incorrect emission factors used for some farms included in list of top 100 ammonia emitters At the request of the Dutch House of Representatives, RIVM compiled a list of the 100 biggest ammonia emitters in the Netherlands. Recently, the underlying data used to compile this list were disclosed pursuant to a request under the Open Government Act.
Cancer screening programmes now more accessible to transgender and intersex persons Since October 2022, is it has become easier for transgender and intersex persons to take part in cervical cancer screening and breast cancer screening. Transgender and intersex persons with a uterus and/or breast tissue can register with Bevolkingsonderzoek Nederland.